Literature DB >> 17473300

MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis.

Mark Bloomston1, Wendy L Frankel, Fabio Petrocca, Stefano Volinia, Hansjuerg Alder, John P Hagan, Chang-Gong Liu, Darshna Bhatt, Cristian Taccioli, Carlo M Croce.   

Abstract

CONTEXT: While global microRNA (miRNA) expression patterns of many embryologic, physiologic, and oncogenic processes have been described, description of the role of miRNAs in ductal adenocarcinoma of the pancreas is lacking.
OBJECTIVE: To define the expression pattern of miRNAs in pancreatic cancer and compare it with those of normal pancreas and chronic pancreatitis. DESIGN AND
SETTING: Specimens were obtained at a National Cancer Institute-designated comprehensive cancer center from patients with ductal adenocarcinoma of the pancreas (n = 65) or chronic pancreatitis (n = 42) (January 2000-December 2005). All patients underwent curative pancreatectomy; those with pancreatic cancer were chemotherapy-naive. RNA harvested from resected pancreatic cancers and matched benign adjacent pancreatic tissue as well as from chronic pancreatitis specimens was hybridized to miRNA microarrays. MAIN OUTCOME MEASURES: Identification of differentially expressed miRNAs that could differentiate pancreatic cancer from normal pancreas, chronic pancreatitis, or both, as well as a pattern of miRNA expression predictive of long-term (>24 months) survival. Significance of Analysis of Microarrays and Prediction of Analysis of Microarrays were undertaken to identify miRNAs predictive of tissue type and prognosis. P values were calculated by t test, adjusted for multiple testing. Kaplan-Meier survival curves were constructed using mean miRNA expression (high vs low) as threshold and compared by log-rank analysis.
RESULTS: Twenty-one miRNAs with increased expression and 4 with decreased expression were identified that correctly differentiated pancreatic cancer from benign pancreatic tissue in 90% of samples by cross validation. Fifteen overexpressed and 8 underexpressed miRNAs differentiated pancreatic cancer from chronic pancreatitis with 93% accuracy. A subgroup of 6 miRNAs was able to distinguish long-term survivors with node-positive disease from those dying within 24 months. Finally, high expression of miR-196a-2 was found to predict poor survival (median, 14.3 months [95% confidence interval, 12.4-16.2] vs 26.5 months [95% confidence interval, 23.4-29.6]; P = .009).
CONCLUSIONS: Pancreatic cancer may have a distinct miRNA expression pattern that may differentiate it from normal pancreas and chronic pancreatitis. miRNA expression patterns may be able to distinguish between long- and short-term survivors, but these findings need to be validated in other study populations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17473300     DOI: 10.1001/jama.297.17.1901

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  536 in total

1.  miR-21 and miR-375 microRNAs as candidate diagnostic biomarkers in squamous cell carcinoma of the larynx: association with patient survival.

Authors:  An Hu; Jing-Juan Huang; Wei-Hua Xu; Xiao-Jie Jin; Ji-Ping Li; Yuan-Jia Tang; Xin-Fang Huang; Hui-Juan Cui; Guang-Bin Sun
Journal:  Am J Transl Res       Date:  2014-10-11       Impact factor: 4.060

Review 2.  Molecular signatures of pancreatic cancer.

Authors:  Seung-Mo Hong; Jason Y Park; Ralph H Hruban; Michael Goggins
Journal:  Arch Pathol Lab Med       Date:  2011-06       Impact factor: 5.534

3.  Polymorphisms of miRNAs genes are associated with the risk and prognosis of coronary artery disease.

Authors:  Hong Zhi; Lina Wang; Genshan Ma; Xingzhou Ye; Xiaojin Yu; Yi Zhu; Yu Zhang; Jiaju Zhang; Bei Wang
Journal:  Clin Res Cardiol       Date:  2011-12-11       Impact factor: 5.460

Review 4.  Aberrant epigenetic grooming of miRNAs in pancreatic cancer: a systems biology perspective.

Authors:  Asfar S Azmi; Frances W J Beck; Bin Bao; Ramzi M Mohammad; Fazlul H Sarkar
Journal:  Epigenomics       Date:  2011-12       Impact factor: 4.778

5.  Environmental chemical exposures and human epigenetics.

Authors:  Lifang Hou; Xiao Zhang; Dong Wang; Andrea Baccarelli
Journal:  Int J Epidemiol       Date:  2011-12-13       Impact factor: 7.196

6.  High dose glargine alters the expression profiles of microRNAs in pancreatic cancer cells.

Authors:  Wei-Guang Li; Yao-Zong Yuan; Min-Min Qiao; Yong-Ping Zhang
Journal:  World J Gastroenterol       Date:  2012-06-07       Impact factor: 5.742

Review 7.  Can we better predict the biologic behavior of incidental IPMN? A comprehensive analysis of molecular diagnostics and biomarkers in intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Kiara A Tulla; Ajay V Maker
Journal:  Langenbecks Arch Surg       Date:  2017-12-07       Impact factor: 3.445

8.  MicroRNAs in Cerebral Ischemia.

Authors:  Kai-Ying Lim; Jia-Hui Chua; Jun-Rong Tan; Priyadharshni Swaminathan; Sugunavathi Sepramaniam; Arunmozhiarasi Armugam; Peter Tsun-Hon Wong; Kandiah Jeyaseelan
Journal:  Transl Stroke Res       Date:  2010-12       Impact factor: 6.829

9.  A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma.

Authors:  Zijian Yang; Michael J LaRiviere; Jina Ko; Jacob E Till; Theresa Christensen; Stephanie S Yee; Taylor A Black; Kyle Tien; Andrew Lin; Hanfei Shen; Neha Bhagwat; Daniel Herman; Andrew Adallah; Mark H O'Hara; Charles M Vollmer; Bryson W Katona; Ben Z Stanger; David Issadore; Erica L Carpenter
Journal:  Clin Cancer Res       Date:  2020-04-16       Impact factor: 12.531

10.  Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support.

Authors:  Scot J Matkovich; Derek J Van Booven; Keith A Youker; Guillermo Torre-Amione; Abhinav Diwan; William H Eschenbacher; Lisa E Dorn; Mark A Watson; Kenneth B Margulies; Gerald W Dorn
Journal:  Circulation       Date:  2009-02-23       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.